MedPath

Renoprotective effect of Calcium channel blocker or Diuretics treatment with Renin-Angiotensin system(RAS) inhibitor in hypertensive patients with chronic kidney disease(CKD) (CD Study)

Not Applicable
Completed
Conditions
Hypertensive patients with CKD under the treatment of the inhibitor of the renin-angiotensin system(RAS)
Registration Number
JPRN-UMIN000004304
Lead Sponsor
iigata University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

1) Secondary hypertension or malignant hypertension(within hypertension in level 3) 2) Severe heart failure(NYHA Class is equal or more than III) 3) Atrial fibrillation or flutter with severe arrhythmia 4) Severe renal failure or liver failure(patient on dialysis, AST or ALT is more than 5 times higher upper limits) 5) Not appropriate for change to the test drugs from current therapy for coronary disease(i.e. CCB, diuretics, etc.) 6) Patient with severe adverse effects by RAS inhibitor, CCB and diuretic 7) Patient has merged the disease seems to be bad, such as malignant tumor prognosis. 8) Type 1 diabetes and type 2 diabetes required hospitalization due to high hemoglobin A1c(equal and more than 9.0%), extremely high blood glucose, or diabetic ketoacidosis. 9) Patients already used other CCB or a diuretic. 10) Pregnant, possible to be pregnant, or willing to be pregnant 11) Patients who are inadequate by determination of physician in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.